Compare Abeona Therapeutics Inc (ABEO) vs AFLAC Incorporated (AFL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs AFLAC Incorporated — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while AFLAC Incorporated trades at $121.28 (market cap $60.70B). The key difference: AFLAC Incorporated is far larger — about 144.1× Abeona Therapeutics Inc's market cap, and AFLAC Incorporated pays a 2.02% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AFL | |
|---|---|---|
Market Cap | $421.19M | $60.70B |
Sector | Health | Financials |
52-Week High | $7.45 | $129.55 |
52-Week Low | $4.17 | $103.55 |
Enterprise Value | $276.10M | $70.65B |
Dividend Yield | — | 2.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
AFL trades at $121.94, down 2.14% with bearish technical signals and recent earnings misses. The stock shows strong profitability with 26.59% net margin and 16.91% ROE, but faces revenue declines from $19.1B in 2024 to $17.4B in 2025. Recent news highlights AFL's rebranding efforts and dividend consistency amid healthcare cost pressures. Technical indicators show oversold RSI at 17.69 with support at $117.
Outlook remains cautious with mixed analyst sentiment (28% buy, 56% hold) and $118 consensus target below current price. Risks include Japan market exposure and currency headwinds, balanced by 43-year dividend growth history and strong cash flow generation. The stock offers value at 13x P/E but requires monitoring of revenue stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →
